MedTrace Logo

Comparison of Sacral Erector Spinae Plane Block and Supra-Inguinal Fascia Iliaca Block for Analgesia After Hip Fracture Surgery

NCT07081867 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 77

Last updated 2026-01-23

No results posted yet for this study

Summary

This study compares the postoperative analgesic effectiveness of Sacral Erector Spinae Plane Block (SESPB) and Supra-Inguinal Fascia Iliaca Block (SIFIB) in patients undergoing hip fracture surgery. Both techniques are regional anesthesia methods aiming to reduce postoperative pain and opioid consumption. The study evaluates pain scores, opioid requirements, mobilization times, and hospital discharge times to determine which block provides more effective pain management in different postoperative periods.

Conditions

  • Hip Fracture Surgery
  • Postoperative Pain Management
  • Regional Anesthesia
  • Elderly Patients

Interventions

PROCEDURE

Sacral Erector Spinae Plane Block (SESPB)

Ultrasound-guided injection of 40 mL of 0.25% bupivacaine into the fascial plane deep to the erector spinae muscle at the sacral level (S2), performed preoperatively for postoperative analgesia in patients undergoing hip fracture surgery under spinal anesthesia.

PROCEDURE

Supra-inguinal Fascia Iliaca Block (SIFIB)

Ultrasound-guided injection of 40 mL of 0.25% bupivacaine between the iliacus muscle and fascia iliaca via a supra-inguinal approach, performed preoperatively for postoperative analgesia in patients undergoing hip fracture surgery under spinal anesthesia.

Sponsors & Collaborators

  • Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization

    lead OTHER

Principal Investigators

  • Beyzanur Aydogdu · Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-15
Primary Completion
2025-06-15
Completion
2025-12-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07081867 on ClinicalTrials.gov